SIS Ventures
VC Fund
Edinburgh, United Kingdom
SIS Ventures is a VC fund in Edinburgh focused on Health Care and Biotechnology. SIS Ventures has been created with the overall aim of supporting and growing high impact organisations through access to mission-aligned investment. SIS Ventures has a goal of becoming the go to investor and partner for social entrepreneurs. The fund will offer conventional financial returns alongside social and/or environmental returns byinvesting either equity or debt into purpose driven companies.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 3%
- Fund size:
- $1M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries SIS Ventures invests in
Stages SIS Ventures invests in
Countries SIS Ventures invests in
Round sizes
Round size
- Seed
- $1.1M–$4.9M
- Series A
- $2.8M–$21M
- Venture - Series Unknown
- $1.6M–$33M
Investment Focus
Industry
- Health Care 7 (21%)
- Biotechnology 7 (21%)
- Medical 5 (15%)
- Manufacturing 3 (9%)
- Machine Learning 3 (9%)
Stage
- Seed 12 (36%)
- Series A 7 (21%)
- Venture - Series Unknown 4 (12%)
- Funding Round 3 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Dxcover
|
Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business hasgenerated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy.Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker. | $6.2M / Feb 03, 2025 | |
|
Dxcover
|
Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business hasgenerated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy.Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker. | $6.2M / Feb 03, 2025 | |
MiAlgae
|
MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market. | $18.5M / Series A / Sep 18, 2024 | |
Solasta Bio
|
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection. | $14M / Series A / Sep 11, 2024 | |
Metacarpal
|
Metacarpal broke the mould by creating the first bionic yet fully mechanical hand prosthesis. Capable of switching grips yet offering responsive and precise control already familiar to the user, they aim to also supply prosthetics to those most in need in the developing world. | $1.1M / Seed / Aug 27, 2024 | |
Nami Surgical
|
Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments. | $3.1M / Seed / May 08, 2024 | |
Nebu-Flow
|
Nebu-Flow is a manufacturer of the next generation of inhaled drugs for patients with respiratory disorders. The company is a developer of the technology control of the droplet size for deep lung deposition by enabling injection-free systemic drug delivery through inhalation routes for cardiovascular and central nerve system disorders. Nebu-Flow iscommitted to minimizing the environmental impact of activities whilst continuing to create a user-friendly and high-performing Nebuliser. | Venture - Series Unknown / Apr 29, 2024 | |
Carcinotech
|
Carcinotech is focused on treating cancers and is based at the Roslin Innovation Centre on the outskirts of Edinburgh. | $5.3M / Seed / Jan 29, 2024 | |
Trojan Energy
|
Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking. | $32.9M / Venture - Series Unknown / Jan 16, 2024 | |
Beta Bugs Limited
|
Beta Bugs is a cutting edge biotechnology company that produces enhanced insect strains for the growing insect farming industry. The domesticated, optimised strains we produce provide benefits at all levels of the production chain ensuring the industry is both more profitable and sustainable. We accelerate the evolution of the organisms to createtraits that ensure greatly superior final products. | $2.1M / Oct 17, 2023 | |
| See all 33 investments → | |||
Co-Investors
Scottish Enterprise
23 deals together
Eos
9 deals together
University of Strathclyde
9 deals together
Equity Gap
8 deals together
Scottish Investment Bank
8 deals together
Alba Equity
6 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SIS Ventures invest in?
SIS Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 33 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SIS Ventures's check size?
SIS Ventures typically joins rounds of $1.1M–$4.9M at Seed, $2.8M–$21M at Series A and $1.6M–$33M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SIS Ventures participates in.
When did SIS Ventures last invest?
The most recent investment recorded for SIS Ventures closed in Feb 2025. Shizune tracks 33 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
